News

Eli Lilly Just Made Another Move to Dominate the Weight Loss Market: Should You Buy the Stock?
Eli Lilly ( LLY 0.90%) is one of the undisputed leaders in the fast-growing market for weight-management medicines. Following ...
This one-and-done heart-disease treatment just got a $1.3 billion endorsement from Eli Lilly
Verve Therapeutics’ stock was rallying by a record 80% on Eli Lilly’s premium purchase price for the drug-development company ...
Eli Lilly: The Buy Case Gets Stronger (Rating Upgrade)
Eli Lilly's stock price has over-corrected following a downgrade in its outlook following the adjustment for acquisition ...
Eli Lilly’s Dividend May Be Small, But its Growth Tells a Bigger Story
Eli Lilly and Company (NYSE:LLY) may offer a modest dividend yield, but its track record of consistent payouts remains strong ...
Fierce Pharma1d
Eli Lilly adds high-dose Zepbound options to lineup of cheaper vials available on self-pay website
Eli Lilly is unleashing self-pay discounts across the entirety of its obesity portfolio with new price cuts for higher doses ...
KYMA1d
Eli Lilly announces price cut for Zepbound
Eli Lilly is reducing the price of the highest doses of its popular drug Zepbound for folks who aren't using insurance.
Explore more